| CYP21A2 |
Hyperandrogenism |
0.838712 |
5 |
TRUE |
Included in national screening panel |
1 |
1 |
0.935485 |
| HBB |
Haemoglobin variant |
0.197344 |
17 |
TRUE |
Included in national screening panel |
0.918184 |
0.918184 |
0.629848 |
| MEFV |
Neutrophilic dermatosis |
0.752691 |
3 |
TRUE |
Included in national screening panel |
0.542552 |
0.542552 |
0.626608 |
| SGCG |
Muscular dystrophy, limb girdle |
1 |
1 |
TRUE |
Included in national screening panel |
0.236572 |
0.236572 |
0.541943 |
| HBD |
Haemoglobin variant |
0.967746 |
1 |
TRUE |
Included in national screening panel |
0.229039 |
0.229039 |
0.524522 |
| F2 |
Thrombophilia 1 due to thrombin defect |
0.677421 |
1 |
TRUE |
Included in national screening panel |
0.16094 |
0.16094 |
0.367532 |
| ABCA4 |
Retinal dystrophy |
0.211982 |
7 |
TRUE |
Included in national screening panel |
0.397026 |
0.397026 |
0.323009 |
| CUBN |
Albuminuria, association with |
0.17742 |
8 |
TRUE |
Included in national screening panel |
0.39329 |
0.39329 |
0.306942 |
| HBA1 |
Haemoglobin variant |
0.333334 |
3 |
TRUE |
Included in national screening panel |
0.253599 |
0.253599 |
0.285493 |
| ABCA12 |
Ichthyosis |
0.483872 |
1 |
TRUE |
Included in national screening panel |
0.115249 |
0.115249 |
0.262698 |
| CD36 |
Platelet glycoprotein IV deficiency |
0.188172 |
6 |
TRUE |
Included in national screening panel |
0.30648 |
0.30648 |
0.259157 |
| ITGB3 |
Bleeding disorder |
0.451614 |
1 |
TRUE |
Included in national screening panel |
0.107611 |
0.107611 |
0.245212 |
| BCHE |
Butyrylcholinesterase deficiency |
0.27957 |
3 |
TRUE |
Included in national screening panel |
0.214307 |
0.214307 |
0.240412 |
| DONSON |
Microcephaly |
0.338711 |
2 |
TRUE |
Included in national screening panel |
0.168675 |
0.168675 |
0.236689 |
| HBA2 |
Haemoglobin variant |
0.322582 |
2 |
TRUE |
Included in national screening panel |
0.161698 |
0.161698 |
0.226051 |
| CYP1B1 |
Glaucoma 3A |
0.258065 |
3 |
TRUE |
Included in national screening panel |
0.199576 |
0.199576 |
0.222972 |
| PAH |
Hyperphenylalaninemia |
0.0537636 |
15 |
TRUE |
Included in national screening panel |
0.300884 |
0.300884 |
0.202036 |
| GJB2 |
Keratoderma |
0.161291 |
5 |
TRUE |
Included in national screening panel |
0.223462 |
0.223462 |
0.198593 |
| SORD |
Neuronopathy, distal hereditary motor, autosomal recessive 8 |
0.35484 |
1 |
TRUE |
Included in national screening panel |
0.0846583 |
0.0846583 |
0.192731 |
| GALNT3 |
Tumoral calcinosis |
0.225807 |
2 |
TRUE |
Included in national screening panel |
0.11556 |
0.11556 |
0.159659 |
| PKLR |
Pyruvate kinase deficiency |
0.161291 |
3 |
TRUE |
Included in national screening panel |
0.13081 |
0.13081 |
0.143002 |
| MPL |
Thrombocytosis, association with |
0.258065 |
1 |
TRUE |
Included in national screening panel |
0.0616473 |
0.0616473 |
0.140214 |
| F7 |
Factor VII deficiency |
0.112904 |
4 |
TRUE |
Included in national screening panel |
0.130816 |
0.130816 |
0.123651 |
| COQ9 |
Primary coenzyme Q10 deficiency, neonatal onset |
0.225807 |
1 |
TRUE |
Included in national screening panel |
0.0539641 |
0.0539641 |
0.122701 |
| NCF1 |
Chronic granulomatous disease |
0.225807 |
1 |
TRUE |
Included in national screening panel |
0.0539641 |
0.0539641 |
0.122701 |
| SLC26A4 |
Deafness |
0.0903227 |
5 |
TRUE |
Included in national screening panel |
0.138933 |
0.138933 |
0.119489 |
| AVIL |
Nephrotic syndrome |
0.193549 |
1 |
TRUE |
Included in national screening panel |
0.0462744 |
0.0462744 |
0.105184 |
| PIGO |
PIGO deficiency |
0.193549 |
1 |
TRUE |
Included in national screening panel |
0.0462744 |
0.0462744 |
0.105184 |
| UFSP2 |
?Hip dysplasia |
0.193549 |
1 |
TRUE |
Included in national screening panel |
0.0462744 |
0.0462744 |
0.105184 |
| ALDH3A2 |
Sjogren-Larsson syndrome |
0.0887098 |
4 |
TRUE |
Included in national screening panel |
0.108123 |
0.108123 |
0.100357 |
| KIF1C |
Cerebellar ataxia |
0.129032 |
2 |
TRUE |
Included in national screening panel |
0.0694861 |
0.0694861 |
0.0933046 |
| HSPG2 |
Scoliosis, idiopathic, association with |
0.0806455 |
4 |
TRUE |
Included in national screening panel |
0.1002 |
0.1002 |
0.092378 |
| TPO |
Thyroid dyshormonogenesis 2A |
0.0645164 |
5 |
TRUE |
Included in national screening panel |
0.107935 |
0.107935 |
0.0905674 |
| AGK |
Sengers syndrome |
0.161291 |
1 |
TRUE |
Included in national screening panel |
0.0385782 |
0.0385782 |
0.0876631 |
| C7 |
Alzheimer disease in Han Chinese, association with |
0.161291 |
1 |
TRUE |
Included in national screening panel |
0.0385782 |
0.0385782 |
0.0876631 |
| C8A |
Complement C8 alpha-gamma deficiency |
0.161291 |
1 |
TRUE |
Included in national screening panel |
0.0385782 |
0.0385782 |
0.0876631 |
| ORC6 |
Meier-Gorlin syndrome |
0.161291 |
1 |
TRUE |
Included in national screening panel |
0.0385782 |
0.0385782 |
0.0876631 |
| RPGRIP1 |
Cone-rod dystrophy 13 |
0.0860216 |
3 |
TRUE |
Included in national screening panel |
0.0772147 |
0.0772147 |
0.0807375 |
| EYS |
Retinitis pigmentosa |
0.0368664 |
7 |
TRUE |
Included in national screening panel |
0.108136 |
0.108136 |
0.0796279 |
| BTD |
Biotinidase deficiency |
0.00992557 |
13 |
TRUE |
Included in national screening panel |
0.123722 |
0.123722 |
0.0782036 |
| TYR |
Albinism, oculocutaneous |
0.0430108 |
6 |
TRUE |
Included in national screening panel |
0.100407 |
0.100407 |
0.0774485 |
| UPB1 |
Beta-ureidopropionase deficiency |
0.075269 |
3 |
TRUE |
Included in national screening panel |
0.0694731 |
0.0694731 |
0.0717915 |
| ABCG8 |
Sitosterolemia 1 |
0.0752689 |
3 |
TRUE |
Included in national screening panel |
0.0694342 |
0.0694342 |
0.0717681 |
| CCDC40 |
Primary ciliary dyskinesia |
0.0967744 |
2 |
TRUE |
Included in national screening panel |
0.0540419 |
0.0540419 |
0.0711349 |
| PCARE |
Retinitis pigmentosa 54 |
0.0967743 |
2 |
TRUE |
Included in national screening panel |
0.0540094 |
0.0540094 |
0.0711154 |
| GLDC |
Glycine encephalopathy |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
| GNE |
GNE myopathy |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
| GP6 |
Absence of collagen-induced platelet activation |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
| GRM6 |
Congenital stationary night blindness |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
| PLOD1 |
Ehlers-Danlos syndrome |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
| PSAP |
Combined SAP deficiency |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
| PTPRQ |
Congenital sensorineural hearing loss, autosomal recessive |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
| VDR |
Rickets |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
| USH2A |
Retinitis Pigmentosa |
0.0201614 |
8 |
TRUE |
Included in national screening panel |
0.0927886 |
0.0927886 |
0.0637377 |
| LAMA1 |
Schizophrenia |
0.0645162 |
3 |
TRUE |
Included in national screening panel |
0.0618028 |
0.0618028 |
0.0628882 |
| ABCC6 |
Pseudoxanthoma elasticum |
0.0387097 |
5 |
TRUE |
Included in national screening panel |
0.0772147 |
0.0772147 |
0.0618127 |
| RAB3GAP2 |
Microphthalmia & cataract |
0.0483872 |
4 |
TRUE |
Included in national screening panel |
0.0695574 |
0.0695574 |
0.0610893 |
| COL17A1 |
Epithelial recurrent erosion dystrophy |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463392 |
0.0463392 |
0.0600616 |
| GNRHR |
Hypogonadotropic hypogonadism |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463392 |
0.0463392 |
0.0600616 |
| NR2E3 |
Retinitis pigmentosa 37 |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463392 |
0.0463392 |
0.0600616 |
| RARS2 |
Pulmonary arterial hypertension |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463392 |
0.0463392 |
0.0600616 |
| CCNO |
Ciliary dyskinesia |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463132 |
0.0463132 |
0.0600461 |
| CDK5RAP2 |
Autism spectrum disorder |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463132 |
0.0463132 |
0.0600461 |
| CDH23 |
Usher syndrome |
0.0268818 |
6 |
TRUE |
Included in national screening panel |
0.0773185 |
0.0773185 |
0.0571438 |
| VWF |
von Willebrand disease |
0.0403227 |
4 |
TRUE |
Included in national screening panel |
0.0618093 |
0.0618093 |
0.0532147 |
| ALDOB |
Fructose intolerance |
0.0967743 |
1 |
TRUE |
Included in national screening panel |
0.0231663 |
0.0231663 |
0.0526095 |
| CNGB3 |
Achromatopsia 3 |
0.0967743 |
1 |
TRUE |
Included in national screening panel |
0.0231663 |
0.0231663 |
0.0526095 |
| PJVK |
Deafness |
0.0967743 |
1 |
TRUE |
Included in national screening panel |
0.0231663 |
0.0231663 |
0.0526095 |
| GAA |
Glycogen storage disease II |
0.0215054 |
6 |
TRUE |
Included in national screening panel |
0.0695833 |
0.0695833 |
0.0503522 |
| MYO5B |
Diarrhea 2 |
0.0645162 |
2 |
TRUE |
Included in national screening panel |
0.0386365 |
0.0386365 |
0.0489884 |
| SLC3A1 |
Cystinuria |
0.0645162 |
2 |
TRUE |
Included in national screening panel |
0.0386365 |
0.0386365 |
0.0489884 |
| ZFYVE26 |
Spastic paraplegia with thin corpus callosum |
0.0645162 |
2 |
TRUE |
Included in national screening panel |
0.0386365 |
0.0386365 |
0.0489884 |
| SLC12A3 |
Gitelman syndrome |
0.0322581 |
4 |
TRUE |
Included in national screening panel |
0.0541002 |
0.0541002 |
0.0453634 |
| GYS2 |
Glycogen storage disease 0 |
0.0430109 |
3 |
TRUE |
Included in national screening panel |
0.0463781 |
0.0463781 |
0.0450312 |
| GALC |
Krabbe disease |
0.0430108 |
3 |
TRUE |
Included in national screening panel |
0.0463651 |
0.0463651 |
0.0450234 |
| SI |
Sucrase isomaltase deficiency |
0.0430108 |
3 |
TRUE |
Included in national screening panel |
0.0463651 |
0.0463651 |
0.0450234 |
| CFTR |
Cystic fibrosis |
0.0193549 |
5 |
TRUE |
Included in national screening panel |
0.0541196 |
0.0541196 |
0.0402137 |
| ACADS |
Short-chain acyl-CoA-dehydrogenase deficiency |
0.0483872 |
2 |
TRUE |
Included in national screening panel |
0.0309144 |
0.0309144 |
0.0379035 |
| SPG7 |
Spastic paraplegia |
0.0483872 |
2 |
TRUE |
Included in national screening panel |
0.0309144 |
0.0309144 |
0.0379035 |
| ANO5 |
Muscular dystrophy, limb girdle 2L |
0.0483872 |
2 |
TRUE |
Included in national screening panel |
0.0309014 |
0.0309014 |
0.0378957 |
| F11 |
Factor XI deficiency |
0.0483872 |
2 |
TRUE |
Included in national screening panel |
0.0309014 |
0.0309014 |
0.0378957 |
| OBSL1 |
Cardiomyopathy, dilated |
0.0241936 |
4 |
TRUE |
Included in national screening panel |
0.0463911 |
0.0463911 |
0.0375121 |
| TRIP4 |
Spinal muscular atrophy & congenital bone fractures |
0.0241936 |
4 |
TRUE |
Included in national screening panel |
0.0463911 |
0.0463911 |
0.0375121 |
| TTC37 |
Fatigue, failure to thrive & diarrhoea |
0.0241936 |
4 |
TRUE |
Included in national screening panel |
0.0463911 |
0.0463911 |
0.0375121 |
| DPYS |
Dihydropyrimidinase deficiency |
0.0107527 |
6 |
TRUE |
Included in national screening panel |
0.0541326 |
0.0541326 |
0.0367807 |
| GCDH |
Glutaric acidaemia 1 |
0.0322581 |
3 |
TRUE |
Included in national screening panel |
0.0386495 |
0.0386495 |
0.0360929 |
| TTC21B |
Bardet-Biedl syndrome |
0.0322581 |
3 |
TRUE |
Included in national screening panel |
0.0386495 |
0.0386495 |
0.0360929 |
| TPRN |
Hearing loss |
0.0322581 |
3 |
TRUE |
Included in national screening panel |
0.0386365 |
0.0386365 |
0.0360851 |
| APTX |
Ataxia |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| B3GALT6 |
Spondyloepimetaphyseal dysplasia with joint laxity |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| C8B |
Primary immunodeficiency disease |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| CERS3 |
Ichthyosis |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| CYP4V2 |
Retinitis pigmentosa |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| HSD11B2 |
Apparent mineralocorticoid excess |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| MOCOS |
Thiopurine-induced toxicity |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| MTRR |
Cleft lip with or without cleft palate |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| PEX6 |
Peroxisome biogenesis disorder 4B |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| PHC1 |
Primary microcephaly |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| PMM2 |
Congenital disorder of glycosylation 1a |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| PSAT1 |
Developmental disorder |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| SAG |
Retinitis pigmentosa, autosomal recessive |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| SBF1 |
Charcot-Marie-Tooth disease |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| SVBP |
Neurodevelopmental disorder with ataxia |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| TMEM107 |
Oral-facial-digital syndrome |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
| DNAH5 |
Primary ciliary dyskinesia |
0.0161291 |
4 |
TRUE |
Included in national screening panel |
0.0386559 |
0.0386559 |
0.0296452 |
| ATP2A1 |
Autism spectrum disorder |
0.0215055 |
3 |
TRUE |
Included in national screening panel |
0.0309274 |
0.0309274 |
0.0271586 |
| KCNJ1 |
Bartter syndrome |
0.0215055 |
3 |
TRUE |
Included in national screening panel |
0.0309274 |
0.0309274 |
0.0271586 |
| CA5A |
Carbonic anhydrase VA deficiency |
0.0215054 |
3 |
TRUE |
Included in national screening panel |
0.0309209 |
0.0309209 |
0.0271547 |
| DPYD |
Dihydropyrimidine dehydrogenase deficiency |
0.0215054 |
3 |
TRUE |
Included in national screening panel |
0.0309209 |
0.0309209 |
0.0271547 |
| IL17RA |
IL-17RA deficiency with bacterial and fungal infections |
0.0215054 |
3 |
TRUE |
Included in national screening panel |
0.0309209 |
0.0309209 |
0.0271547 |
| DNASE1L3 |
Systemic lupus erythematosus 16 |
0.0322582 |
2 |
TRUE |
Included in national screening panel |
0.0231923 |
0.0231923 |
0.0268187 |
| PANK2 |
Neurodegeneration with brain iron accumulation 1 |
0.0322582 |
2 |
TRUE |
Included in national screening panel |
0.0231923 |
0.0231923 |
0.0268187 |
| ADA2 |
Sneddon syndrome |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
| B3GAT3 |
Multiple joint dislocations |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
| CYP11B1 |
Steroid-11 beta-hydroxylase deficiency |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
| FAH |
Tyrosinemia |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
| SBDS |
Shwachman-Diamond syndrome |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
| TMEM138 |
Joubert syndrome 16 |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
| TMPRSS3 |
Hearing loss |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
| CNGA3 |
Achromatopsia 2 |
0.00645164 |
5 |
TRUE |
Included in national screening panel |
0.0386689 |
0.0386689 |
0.025782 |
| TRIOBP |
Developmental disorder |
0.00645164 |
5 |
TRUE |
Included in national screening panel |
0.0386689 |
0.0386689 |
0.025782 |
| ALMS1 |
Alstrom syndrome |
0 |
6 |
TRUE |
Included in national screening panel |
0.0386754 |
0.0386754 |
0.0232052 |
| LOXHD1 |
Deafness |
0 |
6 |
TRUE |
Included in national screening panel |
0.0386754 |
0.0386754 |
0.0232052 |
| ATM |
Ataxia-telangiectasia |
0.00806455 |
4 |
TRUE |
Included in national screening panel |
0.0309338 |
0.0309338 |
0.0217861 |
| CEP290 |
Leber congenital amaurosis 10 |
0.00806455 |
4 |
TRUE |
Included in national screening panel |
0.0309338 |
0.0309338 |
0.0217861 |
| DYNC2H1 |
Asphyxiating thoracic dystrophy |
0.00806455 |
4 |
TRUE |
Included in national screening panel |
0.0309338 |
0.0309338 |
0.0217861 |
| PKHD1 |
Polycystic kidney disease 4 |
0.00806455 |
4 |
TRUE |
Included in national screening panel |
0.0309338 |
0.0309338 |
0.0217861 |
| VPS13B |
Cohen syndrome |
0.00806455 |
4 |
TRUE |
Included in national screening panel |
0.0309338 |
0.0309338 |
0.0217861 |
| DUOX2 |
Hypothyroidism |
0 |
5 |
TRUE |
Included in national screening panel |
0.0309403 |
0.0309403 |
0.0185642 |
| AGXT |
Hyperoxaluria |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| ALPL |
Odontohypophosphatasia |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| ATP7B |
Wilson disease |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| C6 |
Inflammatory bowel disease, very early onset |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| CAPN3 |
Muscular dystrophy, limb girdle 2A |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| CPLANE1 |
Joubert syndrome |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| MVK |
Hyper-IgD syndrome |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| OTOGL |
Hearing impairment |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| PCDH15 |
Usher syndrome 1 |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| SPG11 |
Charcot-Marie-Tooth disease |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| SPTA1 |
Spherocytosis |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
| ACAD8 |
Isobutyryl-CoA dehydrogenase deficiency |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| ACO2 |
Optic atrophy 9 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| AGRN |
Congenital myasthenic syndrome with distal muscle weakness & atrophy |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| AP4S1 |
Spastic paraplegia 52 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| ARSB |
Mucopolysaccharidosis type VI (Maroteaux-Lamy) |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| ASPM |
Microcephaly 5 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| ATP9A |
Neurodevelopmental disorder with poor growth and behavioral abnormalities |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| CFAP410 |
Retinitis pigmentosa |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| CHRNG |
Multiple pterygium syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| CNTN2 |
Hypogonadotropic hypogonadism |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| COL27A1 |
Steel syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| COL6A2 |
Bethlem myopathy 1 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| CRIPT |
Short stature, microcephaly & dysmorphic facies |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| DGAT1 |
Diarrhea |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| DGUOK |
Portal hypertension |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| DHODH |
Miller syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| DNAH9 |
Situs inversus and male infertility |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| DOCK6 |
Adams-Oliver syndrome 2 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| EDARADD |
Ectodermal dysplasia 11A |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| FANCC |
Fanconi anemia |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| FRAS1 |
Congenital anomalies of the kidney and urinary tract |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| G6PC1 |
Glycogen storage disease Ia |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| GALK1 |
Galactokinase deficiency, presenile cataract |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| GDAP1 |
Charcot-Marie-Tooth disease |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| GIPC3 |
Hearing loss, non-syndromic |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| IL12RB1 |
Mycobacterial infection |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| KIAA0586 |
Joubert syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| KLHL7 |
Retinitis pigmentosa 42 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| LAMA3 |
Epidermolysis bullosa, junctional |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| LHX3 |
Hypopituitarism and sensorineural hearing loss |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| LOXL3 |
Myopia 28 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| LRPPRC |
Infantile mitochondrial disease, lethal |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| LRRK1 |
Osteosclerotic metaphyseal dysplasia |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| MALT1 |
Immunodeficiency, combined |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| MCIDAS |
Ciliary dyskinesia |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| MMACHC |
Methylmalonic aciduria and homocystinuria |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| ORC4 |
Lymphoproliferative disorder |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| OTOA |
Hearing loss |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| PEX1 |
Zellweger syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| PGM3 |
Fetal alcohol syndrome, predisposition to |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| PLA2G6 |
Infantile neuroaxonal dystrophy |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| PNPO |
Pyridoxamine 5'-phosphate oxidase deficiency |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| POLG |
Mitochondrial recessive ataxia syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| QDPR |
Dihydropteridine reductase deficiency |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| RAX |
Microphthalmia |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| SKIV2L |
Macular degeneration, age related, reduced risk |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| SLC5A7 |
Neuronopathy |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| SLC6A19 |
Hartnup disorder |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| TPI1 |
Hemolytic anemia due to triosephosphate isomerase deficiency |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
| ADAMTS18 |
Microcornea, myopic chorioretinal atrophy and telecanthus |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| AIRE |
Autoimmune polyendocrinopathy syndrome |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| ALDH7A1 |
Epilepsy |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| CDH3 |
Hypotrichosis |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| CFAP53 |
Dextrocardia and situs disturbances |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| CORO1A |
Haemophagocytic lymphohistiocytosis |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| EXPH5 |
Epidermolysis bullosa, junctional |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| FTCD |
Formiminoglutamic acidura |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| GAMT |
Cerebral creatine deficiency syndrome 2 |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| GRHPR |
Hyperoxaluria II |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| IQCB1 |
Leber congenital amaurosis |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| LDLR |
LDL cholesterol level QTL2 |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| LIFR |
Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| NPHS1 |
Nephrotic syndrome |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| OCLN |
Pseudo-TORCH syndrome 1 |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| OTOG |
Hearing loss, sensorineural |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| PLEKHG5 |
Myopathy |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| PYGM |
McArdle disease |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| RNASEH2A |
Aicardi-Goutieres syndrome 4 |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| ROGDI |
Kohlschütter-Tönz syndrome |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| SEC23B |
Anaemia, dyserythropoietic congenital, type II |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| SERPINF1 |
Osteogenesis imperfecta |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| SLC25A13 |
Intrahepatic cholestasis, neonatal |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| SLC34A1 |
?Fanconi renotubular syndrome 2 |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| TGM1 |
Ichthyosiform erythroderma, congenital, nonbullous |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| TRPM1 |
Night blindness |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
| GBA |
Gaucher disease |
0 |
4 |
TRUE |
Included in national screening panel |
0.0232052 |
0.0232052 |
0.0139231 |
| PRG4 |
Camptodactyly-arthropathy-coxa vara-pericarditis syndrome |
0 |
4 |
TRUE |
Included in national screening panel |
0.0232052 |
0.0232052 |
0.0139231 |
| TMEM67 |
Nephronophthisis 11 |
0 |
4 |
TRUE |
Included in national screening panel |
0.0232052 |
0.0232052 |
0.0139231 |
| ACADVL |
Very long chain acyl-CoA dehydrogenase deficiency |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| CLN3 |
Retinal dystrophy, early-onset |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| COL7A1 |
EBD |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| DNAH11 |
Ciliary dyskinesia |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| NBAS |
Bone, connective tissue, liver, immune system & retinal defects |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| OTOF |
Deafness, non-syndromic |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| PEPD |
Prolidase deficiency |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| RTTN |
Primary microcephaly & primordial dwarfism |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| STRC |
Deafness, non-syndromic |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| TTN |
Muscular dystrophy |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| TUBGCP6 |
Diaphragmatic hernia |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
| ACADSB |
Inborn error of metabolism |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| ADAMTS17 |
Weill-Marchesani syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| ADGRV1 |
Deafness, non-syndromic, autosomal recessive |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| AGL |
Glycogen storage disease 3 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| AHI1 |
Joubert syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| ALG1 |
Congenital disorder of glycosylation |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| ARSA |
Metachromatic leukodystrophy |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| CBS |
Homocystinuria |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| CCDC39 |
Primary ciliary dyskinesia |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| CTNS |
Cystinosis |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| CUL7 |
3-M syndrome 1 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| CYP27A1 |
Cerebrotendinous xanthomatosis |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| DOK7 |
Fetal akinesia deformation sequence 3 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| DYNC2I1 |
Short-rib thoracic dysplasia 8 with or without polydactyly |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| EVC2 |
Ellis-van Creveld syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| GBA2 |
Spastic paraplegia |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| GPR179 |
Autism spectrum disorder |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| HEXA |
[Hex A pseudodeficiency] |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| HGD |
Alkaptonuria |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| HGSNAT |
Mucopolysaccharidosis type IIIC (Sanfilippo C) |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| HPS3 |
Hermansky-Pudlak syndrome 3 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| IDUA |
Hurler syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| INPP5E |
Joubert syndrome 1 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| JAK3 |
Immunodeficiency, severe combined |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| LINS1 |
Intellectual developmental disorder |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| LYST |
Chediak-Higashi syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| MKS1 |
Parkinson disease, early onset |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| MYO15A |
Deafness, non-syndromic, autosomal recessive |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| NPHP1 |
Nephronophthisis 1 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| NPHP4 |
Nephronophthisis 4 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| PROC |
Thrombophilia 3 due to protein C deficiency |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| PTS |
Tetrahydrobiopterin deficiency |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| RAPSN |
Congenital myasthenic syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| RYR1 |
Congenital myopathy 1B |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| SACS |
Spastic ataxia, Charlevoix-Saguenay |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| SCN4A |
Paramyotonia congenita |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| SERPINA1 |
Reduced alpha-1-antitrypsin concentration |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| SLC25A20 |
Carnitine-acylcarnitine translocase deficiency |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| SLC37A4 |
Glycogen storage disease 1b |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| SPATA7 |
Leber congenital amaurosis 3 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| THOC6 |
Intellectual disability |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| TMEM231 |
Meckel syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| UBR1 |
Johanson-Blizzard syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| WRN |
Werner syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
| ABAT |
GABA-transaminase deficiency |
0 |
1 |
NAN |
- |
0 |
0 |
0 |
| ABCC8 |
Hyperinsulinism |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ACADM |
Acyl-CoA dehydrogenase |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ADA |
Adenosine deaminase deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ADAMTS13 |
Reduced expression |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| AIPL1 |
Leber congenital amaurosis IV |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| AKR1D1 |
Bile acid synthesis defect |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ALG2 |
Congenital disorder of glycosylation 1i |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ALG3 |
Congenital disorder of glycosylation |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ALG8 |
Congenital disorder of glycosylation 1h |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ANO10 |
Cerebellar ataxia 3 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ANTXR2 |
Hyaline fibromatosis syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ASAH1 |
Spinal muscular atrophy with progressive myoclonic epilepsy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ASL |
Argininosuccinic aciduria |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ATP13A2 |
Kufor-Rakeb syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ATR |
Pulmonary fibrosis / aplastic anaemia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| B3GALNT2 |
Muscular dystrophy-dystroglycanopathy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| B3GLCT |
Peters-Plus syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| B4GALNT1 |
Spastic paraplegia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| BBS5 |
Phenotype modifier |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| BBS7 |
Bardet-Biedl syndrome, modifier of |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| BBS9 |
Retinitis pigmentosa |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| BCS1L |
GRACILE syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| BLM |
Breast cancer |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| C2CD3 |
Autism spectrum disorder |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| C5 |
Complement C5 deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CABP4 |
Retinal dystrophy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CCDC103 |
Primary ciliary dyskinesia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CCN6 |
Pseudorheumatoid dysplasia, progressive |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CENPJ |
Intellectual disability |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CEP152 |
Seckel syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CHRNE |
Congenital myasthenic syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CLCNKB |
Bartter syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CLMP |
Congenital short-bowel syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CNTNAP1 |
Hypomyelinating neuropathy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| COG7 |
Schizophrenia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| COL18A1 |
Knobloch syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| COX15 |
Hypertrophic cardiomyopathy, early onset |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| COX20 |
Dysarthria, ataxia and sensory neuropathy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CRB1 |
Leber congenital amaurosis 8 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CRB2 |
Congenital nephrosis, Finnish type-like, with cerebral ventriculomegaly & raised alpha-fetoprotein |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| CTSK |
Pycnodysostosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| DARS2 |
Leukoencephalopathy with brainstem & spinal cord involvement |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| DLL3 |
Congenital scoliosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| DNAAF1 |
Neural tube defects |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| DOCK8 |
Immunodeficiency, primary |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| DPAGT1 |
Congenital disorder of glycosylation 1 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| DSP |
Cardiomyopathy, arrhythmogenic right ventricular |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ECEL1 |
Arthrogryposis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ECHS1 |
Short-chain enoyl-CoA hydratase deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ELP1 |
Autism spectrum disorder |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| EPG5 |
Vici syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ERCC2 |
Basal cell carcinoma, reduced risk, association with |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ESPN |
Hearing loss |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| EXOSC3 |
Pontocerebellar hypoplasia 1 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| FA2H |
Spastic paraplegia 35 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| FAM161A |
Retinitis pigmentosa |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| FBP1 |
Fructose-1,6-bisphosphatase deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| FBXO7 |
Parkinsonism, juvenile |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| FH |
Multiple leiomyomatosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| FIG4 |
Amyotrophic lateral sclerosis, sporadic |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| FLVCR1 |
Posterior column ataxia & retinitis pigmentosa |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| FOXRED1 |
Complex I deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| FRRS1L |
Intellectual disability, developmental delay & seizures |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| GALNS |
Mucopolysaccharidosis IVA |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| GBE1 |
Glycogen storage disease 4 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| GFPT1 |
Congenital myasthenic syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| GHR |
Hypogonadotropic hypogonadism |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| GLB1 |
GM1-gangliosidosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| GNPTAB |
Mucolipidosis III alpha/beta |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| GPHN |
Hyperekplexia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| HADHB |
Mitochondrial trifunctional protein deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| HSD17B3 |
Pseudohermaphroditism, male |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| HSD17B4 |
D-bifunctional protein deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| IFT140 |
Leber congenital amaurosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ITGB2 |
Leukocyte adhesion deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ITGB4 |
Hirschsprung disease |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| IVD |
Isovaleric acidemia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| IYD |
Hypothyroidism |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| KCNV2 |
Retinal cone dystrophy 3B |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| KIF7 |
Macrocephaly, multiple epiphyseal dysplasia & facial features |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| LAMB2 |
Pierson syndrome/ nephrotic syndrome type 5 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| LAMC2 |
Epidermolysis bullosa, Herlitz |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| LIG4 |
Marfan syndrome, early-onset |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| LMAN1 |
Factor V and factor VIII deficiency, combined |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| LMBR1 |
Triphalangeal thumbs and preaxial polydactyly |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| LMNA |
Mandibuloacral dysplasia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| LPL |
Hyperlipidaemia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| MAPKBP1 |
Nephronophthisis, late onset |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| MMADHC |
Homocystinuria, cblD type |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| MMUT |
Methylmalonic aciduria |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| MPLKIP |
Trichothiodystrophy, nonphotosensitive |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| MPV17 |
Mitochondrial DNA depletion syndrome, hepatocerebral |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| MRE11 |
Breast cancer |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| NBN |
Breast cancer, male |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| NCF2 |
Chronic granulomatous disease |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| NDUFAF5 |
Leigh syndrome/Mitochondrial Complex I deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| NDUFS1 |
Neurodevelopmental disorder |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| NEK1 |
Amyotrophic lateral sclerosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| NEK8 |
Renal disease with hepatic and cardiac anomalies |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| NKX6-2 |
Spastic ataxia 8 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| NUBPL |
Complex I deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| OPA1 |
Optic atrophy plus syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PC |
Hyperinsulinism |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PCCB |
Propionicacidemia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PDE6B |
Retinitis pigmentosa, pericentral |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PDP1 |
Tourette syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PEX12 |
Peroxisome biogenesis disorder 3B |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PEX16 |
Peroxisome biogenesis disorder 8B |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PEX26 |
Refsum disease, infantile |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PGM1 |
Congenital disorder of glycosylation |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PHGDH |
Neu-Laxova syndrome 1 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PNP |
Nucleoside phosphorylase deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| POR |
Altered function |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PRICKLE1 |
Neural tube defects |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PRUNE1 |
Hypotonia, microcephaly and global developmental delay |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| PYGL |
Glycogen storage disease 6 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| QARS1 |
Microcephaly |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| RAG1 |
Omenn syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| RECQL4 |
Baller-Gerold syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| RFXANK |
MHC class II deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| RNASEH2B |
Aicardi-Goutières syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| RNASEH2C |
Aicardi-Goutieres syndrome 3 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| ROBO3 |
Gaze palsy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SCN9A |
Childhood absence epilepsy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SEPSECS |
Cerebellar atrophy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SGCD |
Muscular dystrophy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SGSH |
Mucopolysaccharidosis type IIIA (Sanfilippo A) |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SLC19A3 |
Wernicke's-like encephalopathy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SLC22A5 |
Carnitine deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SLC25A19 |
Thiamine metabolism dysfunction syndrome 4 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SLC2A1 |
Glucose transporter type 1 deficiency syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SLC35D1 |
Schneckenbecken dysplasia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SLC38A8 |
Foveal hypoplasia, optic nerve decussation defects and anterior segment dysgenesis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SLC39A14 |
?Hyperostosis cranalis interna |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| SMPD1 |
Niemann-Pick disease |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| TMC1 |
Deafness |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| TMCO1 |
Cerebro-facio-thoracic dysplasia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| TMEM237 |
Joubert syndrome related disorder |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| TRAPPC9 |
Hypogonadotropic hypogonadism, normosmic |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| TRMT10A |
Neurodevelopmental disorder |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| TSEN54 |
Intellectual disability & epilepsy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| TTC7A |
Immunodeficiency, combined, with intestinal atresias |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| VARS2 |
Mitochondrial encephalopathy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| VPS33B |
Arthrogryposis, renal dysfunction and cholestasis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| VPS53 |
Parkinson disease, early onset |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| WDR35 |
Short rib-polydactyly syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| WDR62 |
Microcephaly, primary |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| WHRN |
Usher syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| XPNPEP3 |
NPHP-like kidney disease |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
| XYLT1 |
Desbuquois dysplasia 2 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |